|
April 2: Course Overview
__________________________________________________________________________
April 9: Robin Campbell — President and CEO, Naryx Pharma, Inc.
Commercialization: From Bench to Bedside. A descriptor title might be:
"All the things you wished you'd done or thought of earlier, but didn't, to
prepare for market entry"
View Presentation (pdf)
__________________________________________________________________________
April 16: Bruce Altrock — former V.P. Research, Amgen
Overview/tools and considerations for research
View Presentation (pdf)
__________________________________________________________________________
April 23: Terri Burgess — Director of Oncology Research, Amgen
Research in a biotech company
View Presentation (pdf)
__________________________________________________________________________
April 30: Roy Hardiman — V.P. Corporate Law and Assistant Secretary, Genentech
Legal issues/licensing
View Presentation (pdf)
__________________________________________________________________________
May 7: Leslie Edwards — Director of Corporate Business Development for the College of Engineering and Math Life and Physical Sciences at UC Santa Barbara; former Manager of the division pharmacology and toxicology, Miravant
Entrepreneurial Toxicology- a very fun job
View Presentation (pdf)
__________________________________________________________________________
May 14: Linda Pullan — Biotech Business Development Consultant, Pullan Consulting
Business development in emerging biotechnology
View Presentation (pdf)
__________________________________________________________________________
May 21: Ralph Smalling — former V.P. Regulator Affairs, Amgen
Regulatory affairs
View Presentation (pdf)
__________________________________________________________________________
May 28: Geoff Slaff — Senior Vice President, Quality, Amgen
Scale-up and process development
__________________________________________________________________________
June 4: Student presentations
|
